OnKure Therapeutics, Inc. (OKUR) free cash flow
OnKure Therapeutics, Inc. (OKUR) generated free cash flow of -$51.87M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$51.17M. Figures as of 18 Nov 2026, 12:36 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Free cash flow, fiscal 2025
- -$51.87M
- Highest on record
- -$18.56Mfiscal 2020
- Lowest on record
- -$51.87Mfiscal 2025
- Fiscal years on record
- 62020–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
OnKure Therapeutics, Inc. free cash flow, in more detail
Across the 6 fiscal years on record (2020–2025), the highest was -$18.56M in fiscal 2020 and the lowest -$51.87M in fiscal 2025.
Free cash flow by fiscal year
OnKure Therapeutics, Inc. free cash flow, year by year
| Fiscal year | Free cash flow | Change | Year ended |
|---|---|---|---|
| 2025 | -$51.87M | — | |
| 2024 | -$51.17M | — | |
| 2023 | -$34.79M | — | |
| 2022 | -$28.09M | — | |
| 2021 | -$38.18M | — | |
| 2020 | -$18.56M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.
How to read it
It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.
OnKure Therapeutics, Inc., figure by figure
- OnKure Therapeutics, Inc. market cap
- OnKure Therapeutics, Inc. revenue
- OnKure Therapeutics, Inc. earnings
- OnKure Therapeutics, Inc. earnings per share (EPS)
- OnKure Therapeutics, Inc. P/E ratio
- OnKure Therapeutics, Inc. P/S ratio
- OnKure Therapeutics, Inc. P/B ratio
- OnKure Therapeutics, Inc. operating margin
- OnKure Therapeutics, Inc. dividend
- OnKure Therapeutics, Inc. shares outstanding
- OnKure Therapeutics, Inc. total debt
- OnKure Therapeutics, Inc. cash on hand
- OnKure Therapeutics, Inc. total assets
- OnKure Therapeutics, Inc. return on equity (ROE)
- OnKure Therapeutics, Inc. return on invested capital (ROIC)
OnKure Therapeutics, Inc. (OKUR) overview: price, valuation and scorecard
OnKure Therapeutics, Inc. free cash flow: questions and answers
What is OnKure Therapeutics, Inc.'s free cash flow?
OnKure Therapeutics, Inc. (OKUR) generated free cash flow of -$51.87M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$51.17M.
What are the highest and lowest free cash flow figures on record for OnKure Therapeutics, Inc.?
Across the 6 fiscal years on record (2020–2025), the highest was -$18.56M in fiscal 2020 and the lowest -$51.87M in fiscal 2025.
How is OnKure Therapeutics, Inc.'s free cash flow calculated?
Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For OnKure Therapeutics, Inc. it is on record here for 6 fiscal years, 2020 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: free cash flow
All stocks guides →- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
- How a DCF valuation works, and why inputs swing it
A discounted cash flow (DCF) valuation estimates what a business is worth today by forecasting the cash it will produce and discounting each year's cash back at a required rate of return. Because most of the value lies far in the future, a one-point change in growth or discount rate can move the answer by a quarter.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “OnKure Therapeutics, Inc. (OKUR) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/OKUR/free-cash-flow
Underlying data: the company's filings with the SEC and Yahoo Finance.